ARTICLE | Company News
Amylin sales and marketing update
February 20, 2012 8:00 AM UTC
Amylin launched once-weekly Bydureon exenatide in the U.S. to treat Type II diabetes. FDA approved the long-acting release ( LAR) formulation of synthetic exendin-4 that uses drug delivery technolog...